Haemonetics Corporation
HAE Healthcare Medical Devices
Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025.
- Revenue
- +9.30%
- EPS
- +25.9%
- Free cash flow
- +20.4%
- Total debt
- +21.0%
Quarter to September 2026, against a year earlier
Follow HAE
Alert me
Haemonetics Corporation (HAE) EV/FCF
As of 5 November 2026, Haemonetics Corporation (HAE) trades at a EV/FCF of 20.9×. Over the past ten years it has ranged from −195× (November 2015) to 3,721× (March 2016); the current reading is higher than 18% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2026 | 13.9× | (39.70%) |
| FY2025 | 23.0× | (31.95%) |
| FY2024 | 33.8× | (39.68%) |
| FY2023 | 56.1× | 23.62% |
| FY2022 | 45.3× | (45.52%) |
| FY2021 | 83.2× | 101.30% |
| FY2020 | 41.4× | (62.67%) |
| FY2019 | 111× | 345.72% |
| FY2018 | 24.9× | (2.56%) |
| FY2017 | 25.5× | (74.75%) |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 18.2× | 22.78% |
| Jun 2026 | 14.9× | 7.11% |
| Mar 2026 | 13.9× | 0.32% |
| Dec 2025 | 13.8× | 21.80% |
| 43 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| HAE Haemonetics Corporation | 20.9× |
| BIO Bio-Rad Laboratories, Inc. compare | 28.8× |
| BIO.B Bio-Rad Laboratories, Inc. compare | 29.5× |
| LIVN LivaNova PLC compare | 36.0× |
| BRKR Bruker Corporation compare | 38.8× |
| TXG 10x Genomics compare | 58.9× |
| ITGR Integer Holdings Corporation compare | 68.9× |
| AXGN AxoGen, Inc. compare | 118× |
| IRTC iRhythm Holdings, Inc. compare | 598× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on HAE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement